Leuvectin lipid formulation of DNA encoding interleukin-2 regulatory update

VICL received U.S. Patent No. 6,147,055 covering the non-viral delivery of an IL-2 gene to treat cancer. VICL said the patent relates to Leuvectin, which is in Phase II testing to treat renal and pros...